Documents to download

Biological ageing results from the accumulation of damage within cells, leading to a loss of function and, ultimately, cell death.  The underlying mechanisms of ageing are also risk factors in the onset of frailty, disability and long-term disease. This POSTnote examines the biological basis of ageing, the potential to manipulate the ageing process and to use such knowledge to promote better health later in life.

Acknowledgements

POSTnotes are based on literature reviews and interviews with
a range of stakeholders and are externally peer reviewed.
POST would like to thank interviewees and peer reviewers
for kindly giving up their time during the preparation

Dr Aoife Kidy (Alzheimer’s Society)
Dr Mathew Norton (Alzheimer’s Research UK)
Professor Wolf Reik (Babraham Institute)
Dr Jon Houseley (Babraham Institute)
Dame Linda Partridge (University College London)
Professor Lynne Cox (University of Oxford)
Catherine Joynson (Nuffield Council of Bioethics)
Professor Diana Kuh (University College London)
Professor Martin Knapp (London School of Economics)
Professor Mark Hanson (University of Southampton)
Gareth Giles (University of Southampton)
Dr Chandni Jacobs (University of Southampton)
Professor Thomas Von Zglinicki (Newcastle University)
Professor John Mathers (Newcastle University)
Professor Thomas Kirkwood (Newcastle University)
Dr João Pedro de Magalhães (Univesity of Liverpool)
Dr Alison Tedstone (Public Health England)


Documents to download

Related posts

  • COVID-19 vaccines and virus transmission

    COVID-19 vaccines have been deployed in the UK since December 2020. This article examines the impact of COVID-19 vaccines on transmission of the virus. It also considers the potential implications of vaccine-induced protection for easing lockdown restrictions and debate about potential introduction of immunity certification or a vaccine passport scheme.

    COVID-19 vaccines and virus transmission
  • Changing the UK COVID-19 vaccine dosing schedule

    On December 31, 2020 the four UK Chief Medical Officers (CMOs) published a statement announcing changes to the dosing schedule for the second dose of the Pfizer/BioNTech and University of Oxford/AstraZeneca vaccines. It stated that the interval between the first and second dose should be extended from 3–4 weeks to up to 12 weeks. This rapid response examines the evidence behind this decision.

    Changing the UK COVID-19 vaccine dosing schedule